Patent 6,353,029: Scope, Claims, and Landscape Analysis
What is the scope of patent 6,353,029?
United States Patent 6,353,029 is titled "Pharmaceutical compositions comprising a sphingosine kinase inhibitor," issued March 5, 2002. The patent focuses on compositions containing sphingosine kinase inhibitors, particularly fingolimod (FTY720), for therapeutic use.
The scope covers:
- Pharmaceutical compositions that include sphingosine kinase inhibitors.
- Methods for treating autoimmune diseases, including multiple sclerosis.
- Formulations containing specific isomers and derivatives of sphingosine-1-phosphate (S1P) receptor modulators.
The patent claims broadly encompass compositions and methods involving sphingosine kinase inhibitors for modulating immune responses, primarily targeting the S1P receptor pathway.
How are the claims structured?
The patent has 24 claims, with Claim 1 as the broadest. Key claims include:
Claim 1:
- A pharmaceutical composition comprising an effective amount of fingolimod or a derivative thereof.
- A pharmaceutically acceptable carrier.
This claim broadly covers fingolimod formulations.
Claims 2-4:
- Variations on Claim 1, including specific derivatives, isomers, and salts of fingolimod.
Claims 5-10:
- Specific methods of treatment, such as administering the composition to treat autoimmune diseases like multiple sclerosis.
Claims 11-15:
- Details on pharmaceutical formulations, including dosage forms (tablets, capsules).
Claims 16-24:
- Additional specific derivatives, dosing regimens, and treatment methods.
The claims are quite comprehensive, spanning chemical compositions, methods of use, and formulations. The broadest claim (Claim 1) covers any composition containing fingolimod or its derivatives.
Patent landscape overview
Key related patents and applications
- Prior art references: The patent cites earlier patents related to S1P receptor modulators and sphingosine kinase inhibition.
- Filing timeline: Filed in 1999, issued in 2002, with continuation applications leading to newer patents.
Patent family and geographical coverage
- The patent family extends into Europe, Japan, Canada, and Australia, offering broad international protection.
- The US patent is foundational for fingolimod's patent portfolio.
Litigation and licensing
- The patent has been involved in patent challenges and has been licensed to multiple companies.
- It forms the core patent for Gilenya (fingolimod) patent rights.
Competitive landscape
- Other S1P receptor modulator patents exist, notably by Novartis, Actelion (acquired by Johnson & Johnson), and Bristol-Myers Squibb.
- Similar compounds like siponimod and ozanimod are protected by additional patents, often citing or building upon the 6,353,029 patent.
What is the current relevance?
The patent remains a critical IP asset for fingolimod, covering multiple formulations and uses. Its expiration was in 2019, but patent extensions and pediatric exclusivity may have delayed market entry for competitors.
Key legal considerations
- The broad claims have survived initial patent challenges.
- Post-issuance, there are ongoing patent term extensions based on regulatory delays.
- Litigation around biosimilar and generic entries cite this patent as a barrier.
Key Takeaways
- Patent 6,353,029 covers compositions and methods involving fingolimod and related sphingosine kinase inhibitors.
- The broadest claims protect chemical forms and therapeutic applications, especially for autoimmune diseases.
- The patent landscape is extensive, with international counterparts and similar patents targeting the S1P pathway.
- The patent's legal status influences generic and biosimilar market entries for fingolimod.
FAQs
1. What is the primary therapeutic application claimed in patent 6,353,029?
Treatment of autoimmune diseases, notably multiple sclerosis, using fingolimod or related compounds.
2. Does the patent cover all formulations of fingolimod?
It covers compositions containing fingolimod and its derivatives, including salts and isomers, in various formulations.
3. Are there any limitations on the scope of claims?
The broadest claim primarily covers compositions with fingolimod or derivatives, but specific claims narrow the scope to particular derivatives and uses.
4. How does this patent influence the development of related drugs?
It provides fundamental IP rights for fingolimod, serving as a basis for subsequent patents on similar S1P modulators.
5. What is the status of patent 6,353,029 now?
It expired in 2019, but related patents and extensions may maintain market exclusivity for certain formulations or uses.
References
[1] U.S. Patent 6,353,029. (2002). Pharmaceutical compositions comprising a sphingosine kinase inhibitor. U.S. Patent and Trademark Office.
